The results of the Hypertension in Diabetes study, embedded within the United Kingdom Prospective Diabetes Study (UKPDS), have recently been published. [1] [2] [3] [4] [5] The UKPDS was designed to examine the impact of improved glycaemic control on the development and progression of macrovascular or microvascular complications in patients with newly diagnosed type 2 diabetes mellitus. It further evaluated whether any particular form of therapy (insulin, sulphonylureas or metformin) was particularly advantageous. However, the high prevalence of hypertension in a subset of the patients and the prospective evaluation of risk factors for coronary artery disease resulted in the inclusion of blood pressure treatments into the study.
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It is well established that patients with type 2 diabetes have a two-fold to three-fold increased incidence of macrovascular events; those who present in their 40-50s have a two-fold increase in total mortality, mainly from cardiovascular diseases. In the UKPDS, 9% of patients developed a microvascular disease within 9 years of diagnosis of diabetes, but 20% experienced a macrovascular complication, including a myocardial infarction in 11%. Macrovascular diseases, predominantly myocardial infarction and stroke, accounted for 59% of deaths. 6 The modifiable risk factors for macrovascular complications have been well identified and these include dyslipidaemia (high LDL or low HDL cholesterol levels), high blood pressure, hyperglycaemia and smoking. 7 The prevalence of hypertension in type 2 diabetes is twice that in the general population, with a prevalence of 40-60% over the age range of 45-75. Interestingly, the UK studies suggest that increased blood pressure is a stronger risk factor for macrovascular events than increased blood glucose levels, with a 15% increased risk for each 10 mm Hg Correspondence: Dr HAA Ibrahim Received and accepted 17 December 1998 increase in blood pressure compared with an 11% for each 1% increase in HbA1c.
Started in 1987 (with a total of 1148 patients followed up for a median of 8.4 years, mean age 56, mean blood pressure at entry 160/94 mm Hg), the Hypertension in Diabetes study was a randomised controlled trial designed to compare tight blood pressure control aiming at a blood pressure of Ͻ150/85 mm Hg (with the use of captopril or atenolol as initial treatments) with less tight control aiming at a blood pressure of Ͻ180/105 mm Hg (with the use of frusemide, nifedipine, methyldopa or prazosin but avoiding angiotensin-converting enzyme inhibitors or ␤-blockers). The study achieved a mean difference of systolic blood pressure of 10 mm Hg and a diastolic pressure of 5 mm Hg (144/82 mm Hg in the tight control group vs 154/87 mm Hg in the less tight control; P Ͻ 0.0001). At 9 years the proportion of patients with both a systolic blood pressure of Ͻ150 mm Hg and a diastolic blood pressure of Ͻ85 mm Hg was 56% in the group assigned to tight control and 37% in the group assigned to less tight control.
Despite this relatively small difference in blood pressure levels between the two groups, the tight control group demonstrated a significant reduction in the risks for most (but not all) of the end-points. These represented a 24% reduction in risk for any diabetes related end-points, 32% for diabetes related death, 44% for fatal and non-fatal stroke, 56% for heart failure and 37% for microvascular complications (mainly retinopathy and predominantly due to a reduction in need for photocoagulation with an accompanying reduced risk of 47% of vision declining by three lines). Indeed, the study was the first to show that tight blood pressure control in patients with type 2 diabetes significantly reduces the rate of deterioration in visual acuity, which is predominantly determined by diabetic maculopathy. The reduction in risks for myocardial infarction (21%) and all-cause mortality (18%) demonstrated a strong trend but were not statistically significant. In comparison, intensive blood glucose control in the main study decreased significantly only the risk of any diabetes related end-point by 12% (P = 0.029) and microvascular disease by 25% (P = 0.0099), with borderline significant reduction in myocardial infarction (16%, P = 0.052).
The number of diabetic patients with hypertension needed to be treated over 10 years to prevent one patient developing any complication was 6.1 (95% confidence interval 2.6-9.5) and to prevent death from a cause related to diabetes was 15.0 (21.1-17.9). Treatment of 1000 of these patients for 10 years could prevent 162 complications and 67 diabetes related deaths. These considerable benefits of tight blood pressure control were cost-effective and compare very favourably with well accepted initiatives such as the implementation of cholesterol lowering for secondary prevention of coronary artery disease, population screening for cardiovascular risk and breast cancer screening, and other well established health care programmes, at least in the UK. Furthermore, we need to be aware that the benefits of tight blood pressure control were larger and appeared sooner compared with intensive glycaemic control.
Whilst not particularly designed to compare differing classes of antihypertensive agents, the UKPDS has also shown that an angiotensin-converting enzyme inhibitor (captopril) and a ␤-blocker (atenolol) were equally effective in achieving tight blood pressure control, and in reducing the risks for macrovascular and microvascular complications. This suggests that blood pressure reduction itself may be more important than the treatment used to achieve it, at least as far as these two types of drugs are concerned, although larger and longer term studies may be needed to assess the effects on distant specific end-points. Compliance with captopril was slightly better than with atenolol, with 78% of those allocated captopril and 65% of those allocated atenolol were taking the drug at their last clinic. The development of cold feet, intermittent claudication, or bronchospasm were the main reasons for this lower rate of compliance. In patients allocated captopril, deterioration in renal function did not appear to be a significant problem, and only 4% of them discontinued the treatment because of a cough. Those given atenolol gained slightly more weight (3.4 kg vs 1.6 kg) and showed a slightly greater increase in the glycosylated haemoglobin and received an additional hypoglycaemic treatment but there was no overall difference in the rates of hypoglycaemia between the two groups.
At 9 years, 29% of patients in the tight control group (27% in the captopril group and 31% in the atenolol group) needed three or more antihypertensive agents compared with 11% in the less tight control group, and over 60% of the patients have required two or more agents. Nifedipine, as an addon medication, was used in 32% of patients in the less tight control group and in 31% and 40% in the tight control group taking captopril and atenolol respectively. These points demonstrate that combined use of different antihypertensive agents is frequently needed and that the UKPDS does not support a significantly deleterious effect for nifedipine.
Unfortunately, hypertension remains under-recognised and under-treated in the diabetic as well as the general population. In the 1995 health survey for England 40% of the general population with hypertension (WHO criteria: Ͼ160 mm Hg systolic, Ͼ95 mm Hg diastolic) were not treated and one-third of the treated subjects still had a blood pressure greater than 160/95 mm Hg. The various guidelines, recommend target blood pressure levels in diabetic patients of Ͻ140/90 mm Hg, 8 Ͻ140/85 mm Hg, 9 or Ͻ130/85 mm Hg. 10 Indeed, some consider a blood pressure of Ͻ160/95 mm Hg 8 or Ͻ160/90 mm Hg 9 as 'acceptable' or 'fair'. These recommendations are based on studies in the general population on the assumption that data relating to hypertensive nondiabetic subjects also applied to those with type 2 diabetes. In the light of UKPDS results, which confirm that lower blood pressure targets in patients with type 2 diabetes result in prevention of both macrovascular and microvascular diseases, the above recommendations for less tight blood pressure control need to be reviewed.
The results of the UKPDS have demonstrated unequivocally, the benefits of even small reductions in blood pressure in patients with type 2 diabetes. These results are further supported by the Hypertension Optimum Treatment (HOT) study, 11 the Systolic Hypertension in the Elderly Program (SHEP) 12 and the Systolic Hypertension in Europe (Syst-Eur) Study.
13, 14 The HOT study, which included a subgroup of 1501 patients with diabetes, provides strong evidence that intensive blood pressure therapy (based on a calcium channel blocker, with various combinations if needed) is beneficial. In particular, the especially striking higher cardiac protection seen in the group achieved a mean diastolic blood pressure of 81.1 mm Hg compared with the group that achieved a mean of 85.2 mm Hg among the diabetic patients confirms the importance of intensive treatment of this highly vulnerable population. Further analysis of the HOT study also demonstrates the concept of the benefits induced by lowering blood pressure from the values prevailing at the time of randomisation into the normotensive range, down to and below the upper normal limit of 140/90 mm Hg, with maximum benefits of treatment expected at systolic values between 130-140 mm Hg and diastolic values between 80-85 mm Hg.
The SHEP study, with its subgroup of 583 diabetic patients, demonstrates that treatment of elderly patients with isolated systolic hypertension (average blood pressure at randomisation was 170/77 mm Hg) result in a significant reduction of major cardiovascular events. The actively treated group achieved a mean blood pressure of 143/68 mm Hg (by using a low-dose diuretic with additional atenolol or reserpine if needed) compared with a mean blood pressure of 155/72 mm Hg in the placebo group. These findings were also supported by the Syst-Eur Study which included a subgroup of 492 patients with diabetes (average blood pressure at randomisation was 173/85 mm Hg) and showed a significant reduction in all cardiovascular end-points and mortality in the group treated actively with a calcium channel blocker, combined with additional treatments if needed (achieved a mean blood pressure of 150/78 mm Hg vs 160/83 mm Hg in the placebo group). In both studies, the absolute risk reduction with active treatment compared with placebo was greater in diabetic vs non-diabetic patients, reflecting the higher risk of diabetic patients and the benefits of tight blood pressure control, even in those who have isolated systolic hypertension.
In conclusion, the UKPDS which is an important landmark in the history of diabetes, has provided answers to important questions and do offer clinicians the opportunity to practise evidence-based medicine when dealing with patients who have type 2 diabetes. What are the important messages? The most important is that we should aim for tight blood pressure control in the diabetic hypertensive population. Even small reductions in blood pressure have larger benefits and these are manifest sooner than those of tight glycaemic control. Combination treatment is frequently needed and agents from different antihypertensive classes are useful, as it seems that the blood pressure levels achieved are probably more important than the agents used. There is a need to review some of the current guidelines which should define, not only target blood pressure values, but also clarify those at which antihypertensive treatment should be commenced. Reflecting on all the above results, target blood pressure values should be defined as a systolic pressure between 130-140 mm Hg and a diastolic pressure between 80-85 mm Hg. Finally, we have to emphasise that proper implementation of the new findings will need a programme of education for all health care professionals, people with diabetes and the public. Involvement of patients in understanding the concept of cardiovascular risk is crucial, as it is expected that they would need more treatments to achieve the new goals that have been shown to be effective in reducing the high morbidity and mortality caused by diabetes and hypertension.
